NasdaqCM - Nasdaq Real Time Price
USD
Immix Biopharma, Inc. (IMMX)
8.06
+0.86
(+11.94%)
At close: November 6 at 4:00:01 PM EST
7.99
-0.07
(-0.87%)
After hours: November 6 at 4:17:02 PM EST
Trade IMMX on Coinbase
Trading disclosure
The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for certain activity generated through this link. Prices displayed are informational.
Learn moreKey Executives
Amounts are as of December 31, 2025 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.
| Name | Title | Pay | Exercised | Year Born |
|---|---|---|---|---|
|
Dr. Ilya Rachman M.B.A., M.D., Ph.D.
|
Co-Founder, CEO, Chief Scientific Officer & Chairman | 760k | -- | 1973 |
|
Mr. Gabriel Morris B.A.
|
President, CFO & Director | 760k | -- | 1987 |
|
Dr. Vladimir P. Torchilin D.Sc., MSE, Ph.D.
|
Scientific Co-Founder | -- | -- | 1947 |
|
Dr. Graham Ross FFPM, M.D.
|
Chief Medical Officer & Head of Clinical Development | 88.59k | -- | 1960 |
|
Dr. David Marks MBBS, Ph.D.
|
Chief Medical Officer of Cell Therapy | -- | -- | -- |
|
Mr. Mel Davis-Pickett
|
Head of CMC Technical Development | -- | -- | -- |
|
Mr. Michael A. Grabow
|
Chief Commercial Officer | -- | -- | -- |
Immix Biopharma, Inc.
11400 West Olympic Boulevard
Suite 200
Los Angeles, CA 90064
United States
- Sector:
- Healthcare
- Industry: Biotechnology
- Full Time Employees:
- 21
Description
Immix Biopharma, Inc., a clinical-stage biopharmaceutical company, engages in the development of chimeric antigen receptor cell therapy in light chain Amyloidosis and immune-mediated diseases in the United States and Australia. The company' lead product is NXC-201 for relapsed/refractory AL Amyloidos. Immix Biopharma, Inc., was incorporated in 2012 and is headquartered in Los Angeles, California.
Corporate Governance
Immix Biopharma, Inc.’s ISS Governance QualityScore as of November 1, 2026 is 7. The pillar scores are Audit: 9; Board: 5; Shareholder Rights: 7; Compensation: 8.
Corporate governance scores courtesy of
Institutional Shareholder Services (ISS)
Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.
Upcoming Events
November 9, 2026 at 9:00 PM UTC
Immix Biopharma, Inc. Earnings Date
